As many predicted, the FDA approved Biogen Idec Inc.'s multiple sclerosis drug Tysabri (formerly known as Antegren) as a combination and monotherapy for relapsing forms of the disease, but the company and partner Elan Corp. plc did not disclose pricing for the would-be blockbuster. (BioWorld Today)

For analysts eagerly anticipating developments with Antegren, Elan Corp. plc's multiple sclerosis drug, the news last week that Prialt, its first pain product, gained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use was a pleasant sideshow. (BioWorld International)

Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)